+ All Categories
Transcript
Page 1: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Finnish perspective to the Personalised

Medicine while Bridging towards

Horizon 2020

EuroBioForum 2012, 18 April

Merja Hiltunen, MD, PhD

Counsellor, Research and Innovation

Tekes Brussels Office

Embassy of Finland

10-2011 DM 913958

Page 2: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Tekes the Finnish Funding Agency

for Technology and Innovation

03-2011 DM 607668

Page 3: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Public sector activities of R&D in Finland

Academy of

Finland

Universities

Ministry of Employment

and the Economy

Sitra

Finnvera plc

Finpro

Finnish Industry

Investment Ltd

PARLIAMENT

GOVERNMENT

VTT, Technical Research

Centre

Tekes

Regional ELY-Centres

Other ministries and their institutes

Ministry of Education and

Culture

Research and Innovation

Council

Page 4: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Tekes R&D funding in 2011 Total 610 milj. € euros and 1 928 projects

R&D grants to companies and

public organisations 225 milj. €

R&D loans for companies 101 milj. €

Research funding for universities, research institutes and polytechnics 203 milj. €

01-2012 DM 840918 ja 450969

Funding for SHOK research programmes 81 milj. €

The funding for R&D includes 18 million euros from EU Structural Funds.

Research programmes of the Strategic Centres for Science, Technology and Innovation (SHOK) are joint programmes for research organisations and companies.

Page 5: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Strategic research areas

determined by the Strategic

Centres for Science,

Technology and

Innovation

Value creation based on service solutions and intangible assets

Business in global value networks

Renewing services and production by digital means

Natural

resources and

sustainable

economy

Intelligent

environments

Vitality

of people

Focus areas of Tekes strategy

DM 909717

Page 6: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

1) What is the state of affairs in Personalised Medicine in your region / country / organisation?

Tekes Pharma Programme (2008-2011) promoted personalised medicine by funding research and development public and company projects where new molecular biology tools and biomarkers were developed for diagnostic purposes.

• The programme strengthened cooperation with pharmaceutical non-clinical and clinical research networks and funded the development of a national operations model for clinical research in Finland.

FiDiPro – Finland Distinguished Professor Programme implemented and financed by the Academy of Finland and Tekes, provides competitive grants to projects recruiting both international and expatriates, highly merited scientists who are able to commit to long-term cooperation with a Finnish university or research institute.

• With respect to Personalised Medicine, Tekes has funded two FiDiPro projects, which will continue until the end of the year 2014.

10-2011 DM

Page 7: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Pharma

Pharma Programme themes (2008-2011)

Predictive models and methods

accelerating and supporting

the drug development process Patient samples and registry data

to support research

Identifying and exploiting biomarkers

Understanding pathogenetic

mechanisms as well as pharmaco-

kinetics and mechanisms of action

Chemical production technology

and innovative medical

formulations Solutions for synthesis and development

of cost effective synthetic pathways

New production technologies for

promising drug candidates and generic

medicines

Innovative drug formulations for children,

the elderly and for veterinary use

Drug delivery technologies

The development of a

national operational model

for clinical drug research Reformation and harmonisation

of clinical processes and

operations

Development of therapy-specific

clusters

Networked business models Developing business skills

Production of innovations and

access of new products to the

market

Page 8: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

FinnTrials - Tekes funded Pharma Programme project of five Finnish University hospitals

Project aims to develop a national operational model with internet based supportive administrative services for clinical research

The project will create unified principles of action and the single point of access to speed the feasibility of clinical trials in Finland

FinnTrials has made possible for national clinical research organisations to operate as a network in Finland to achieve better results of each hospital district projects

Connections has been built to ECRIN (European Clinical Research Infrastructures Network) collaborations, too

Page 9: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Personalised Medicine as a part of FiDiPro Programme

FiDiPro project 1:

“Translational Research and Personalised Medicine”

• FiDiPro Professor Jonathan Knowles

• Finnish host organisation:

University of Helsinki, Institute for Molecular Medicine Finland

(FIMM); Director, Professor Olli Kallioniemi

10-2011 DM

Page 10: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Personalised Medicine as a part of FiDiPro programme

FiDiPro project 2:

“Systems Biology of Cancer: Mapping, Methods and Modeling for

the Cancer Genome”

FiDiPro Professor Wei Zhang

Finnish host organisation:

Tampere University of Technology, Department of Signal

Processing; Professor Olli Yli-Harja

10-2011 DM

Page 11: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Priorities

DM 909717

• Health promotion

• Preventive healthcare

• Personalised solutions for wellbeing

• Intelligent monitoring

• Utilization of data resources

• Efficient and high-quality social and health care

service system

• Work and learning that regenerate human skills

and capabilities

• Affective and meaningful free time experiences

Vitality of people

Page 12: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Current priority: Personalised health and wellbeing

Tekes Call for proposals 1.1- 28.2.2012 CLOSED

- Strategic openings of research groups

-Public research

-Excellence and high level competences for future businesses

10-2011 DM

Vitality of people

Page 13: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

2) What are the challenges for your region / country / organisation?

Implementing personalised medicine will require a high degree of collaboration amongst the many stakeholders in the life science and medical sectors

Implementation of Medicines Policy 2020 of Ministry of Social Affairs and Health • The document Medicines Policy 2020 (Towards efficient, safe, rational and cost-effective

use of medicines) reports on the joint objectives of the social welfare and healthcare authorities and stakeholders in the field of medicines by the year 2020.

National network and operating model for biobanks is needed • Strategic plan and vision

• Resources needed

• Competitive knowledge and business base. Efforts by academia and industry need to be stepped up

• Biobank Act is intended to come into force in Finland at the beginning of 2013. It sets new standards on research use of human origin

• European level collaboration (eg. Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) is important, too

Page 14: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Horizon 2020 - Priorities for Tekes

1. Broad concept of innovation

2. New forms of innovation activities and user-orientation

3. SME-instrument (and other SME funding modalities)

4. Key enabling competences

5. Evaluation with various excellence criteria

Horizon 2020 has excellent starting point, orientation and target.

03-

2008 DM 369407

Page 15: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

3) What is your expectation of the Horizon 2020 programme and where do you see opportunities for collaboration?

Health, demographic change and wellbeing

• Corresponding elements and themes in Horizon 2020 as in our strategy

Research infrastructures

• Access to high-level infrastructures (such as BBMRI and Elixir) - valuable

SME involvement

• Strategic investments in key enabling technologies – key competencies

Innovative Medicines Initiative (IMI)

• According to the Horizon 2020 proposal, existing public-private partnerships

(PPPs) like IMI may continue to receive support - an opportunity for

collaboration

FET Flagships - potential

10-2011 DM

Page 16: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Personalised medicine is an emerging field which will potentially

bring radical change to healthcare.

It is important to create a better understanding of the value of

molecular diagnostics both to cost effective health care and

better patient outcomes in Europe.

10-2011 DM

Future prospects

Page 17: Finnish Perspective to the Personalised Medicine while Bridging towards Horizon 2020

Copyright © Tekes

Thank You!

Tekes' activities

www.tekes.fi/en

[email protected]


Top Related